Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis

Br J Haematol. 2019 Jun;185(5):998-1001. doi: 10.1111/bjh.15693. Epub 2018 Nov 22.

Authors

Kristen L McCausland¹, Tiffany P Quock², Avery A Rizio¹, Martha S Bayliss¹, Michelle K White¹, Spencer D Guthrie³, Vaishali Sanchorawala⁴

Affiliations

¹ Patient Insights, Optum, Johnston, RI, USA.
² Medical Affairs, Prothena Biosciences Inc, South San Francisco, CA, USA.
³ Biopharma Strategic Consulting, LLC, San Francisco, CA, USA.
⁴ Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.

PMID: 30467849
DOI: 10.1111/bjh.15693

No abstract available

Keywords: AL amyloidosis; NT-proBNP; SF-36; cardiac biomarker; health-related quality of life.

MeSH terms

Adult
Aged
Aged, 80 and over
Biomarkers / metabolism*
Cross-Sectional Studies
Female
Heart Diseases / diagnosis*
Humans
Immunoglobulin Light-chain Amyloidosis / complications*
Male
Middle Aged
Quality of Life / psychology*

Substances

Biomarkers